Cross-Sector entity
Catalyst Pharmaceuticals is most often covered alongside Agamree, which appears in 2 of these 3 stories. The clearest coverage concentration is earnings: 1 of 3 stories, with the rest divided among 2 other categories. The tracked stories average 2 original sources each.
3 verified stories tracked
Last mentioned: Feb 24, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Catalyst Pharmaceuticals is most often covered alongside Agamree, which appears in 2 of these 3 stories. The clearest coverage concentration is earnings: 1 of 3 stories, with the rest divided among 2 other categories. The tracked stories average 2 original sources each. Catalyst Pharmaceuticals appears in 3 tracked Cross-Sector stories from February 24, 2026.
Computed from the 3 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Catalyst Pharmaceuticals. Shared-story counts are live from our verified record — not editorial picks.
Root and Catalyst Pharmaceuticals are scheduled to report quarterly results on Wednesday, offering investors a dual look at high-growth technology and healthcare resilience. Both companies face critical tests regarding their respective expansion strategies and bottom-line improvements in a shifting macroeconomic environment.
Catalyst Pharmaceuticals (CPRX) and Root (ROOT) are scheduled to release their quarterly financial results this Wednesday, February 25. For Catalyst, the report will be a critical barometer for the commercial uptake of its newly launched DMD treatment, Agamree, and the continued stability of its flagship LEMS therapy, Firdapse.
Root and Catalyst Pharmaceuticals are scheduled to release their quarterly financial results this Wednesday, providing critical data points for the insurtech and orphan drug sectors. Investors are looking for Root's progress toward profitability and Catalyst's continued dominance in the LEMS market.
Source: tickerreport.com · dailypolitical.com
